Similar articles

• [The role of quinolones in the treatment of community acquired pneumonia].

  Garau J. Garau J. Med Clin (Barc). 1998 Feb;110 Suppl 1:31-5. Med Clin (Barc). 1998. PMID: 9717158 Spanish. No abstract available.
• Respiratory fluoroquinolones: differences in the details.

  Mandell LA, Iannini PB, Tillotson GS. Mandell LA, et al. Clin Infect Dis. 2004 May 1;38(9):1331-2; author reply 1332-3. doi: 10.1086/383153. Clin Infect Dis. 2004. PMID: 15127351 No abstract available.
• [Oral fluoroquinolones. Rational antibiosis as needed].

  [No authors listed] [No authors listed] MMW Fortschr Med. 1999 Sep 2;141(35):58-9. MMW Fortschr Med. 1999. PMID: 10897964 German. No abstract available.
• [Is trovafloxacin an antibiotic exclusively for the treatment of respiratory infections?].

  Garau J. Garau J. Enferm Infecc Microbiol Clin. 1998 Dec;16 Suppl 2:43-6; discussion 47-52. Enferm Infecc Microbiol Clin. 1998. PMID: 10344098 Review. Spanish. No abstract available.
• [Other communal respiratory pathogens and new fluoroquinolones].

  Cantón R, Loza E, Valdezate S, Baquero F. Cantón R, et al. Enferm Infecc Microbiol Clin. 1998 Dec;16 Suppl 2:12-21; discussion 47-52. Enferm Infecc Microbiol Clin. 1998. PMID: 10344094 Review. Spanish. No abstract available.